CureVac SE
General information
CureVac SE
Friedrich-Miescher-Str. 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Sarah Fakih, Vice President, Corporate Communications & IR
Company main phone: +49 (70) 7198830
Website: https://www.curevac.com
Friedrich-Miescher-Str. 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Sarah Fakih, Vice President, Corporate Communications & IR
Company main phone: +49 (70) 7198830
Website: https://www.curevac.com
| Year founded: | 2000 |
| Source of foundation: | Spin-off from university |
| Name of foundation source: | University of Tuebingen |
| No. of employees: |
Worldwide: 825 |
Corporate description / mission:
CureVac is a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”). The company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.
CureVac is a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”). The company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.
State of ownership: Private / independent
Headquarters: HQ: Yes
IPO (year): 2020
Headquarters: HQ: Yes
IPO (year): 2020
Remarks on ownership / listings
CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S.
CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S.
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 6 | |
| Phase I: | 5 | |
| Phase II: | 5 |
Description of products:
Seasonal Influenza vaccine candidate - B strain optimization (Modified mRNA)
Seasonal Influenza vaccine candidates (Modified mRNA)
Avian Influenza (H5N1)
FLU SV mRNA, etc.
Seasonal Influenza vaccine candidate - B strain optimization (Modified mRNA)
Seasonal Influenza vaccine candidates (Modified mRNA)
Avian Influenza (H5N1)
FLU SV mRNA, etc.
Special IP situation:
The company currently has approximately 800 granted patents.
The company currently has approximately 800 granted patents.
Technology used:
RNActive®
RNArt®
RNAntibody®
RNAdjuvant®
RNActive®
RNArt®
RNAntibody®
RNAdjuvant®
Financing details
Fiscal year (end of) 2024
| Revenues: | USD 560.28M | |
| R&D expenses: | USD 160.21M | |
| Net earnings: | USD 169.79M | |
| Cash: | USD 504.34M |
| Total liabilities: | USD 111.20M | |
| No. of shares: | 225'159'008 | |
| Market cap. / valuation: | USD 1'254.14M |
Collaborations & Clients
Partnering strategy / collaborations:
The University of Texas MD Anderson Cancer Center
Bill & Melinda Gates Foundation
CRISPR Therapeutics, etc.
The University of Texas MD Anderson Cancer Center
Bill & Melinda Gates Foundation
CRISPR Therapeutics, etc.
© 2025 Biotechgate by Venture Valuation